


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61N 1/36	A1	(11) International Publication Number: WO 92/19318 (43) International Publication Date: 12 November 1992 (12.11.92)
<p>(21) International Application Number: PCT/US92/03447</p> <p>(22) International Filing Date: 1 May 1992 (01.05.92)</p> <p>(30) Priority data: 695,558 3 May 1991 (03.05.91) US</p> <p>(71) Applicant: CYBERONICS, INC. [US/US]; Suite 100, 17448 Highway 3, Webster, TX 77598 (US).</p> <p>(72) Inventors: TERRY, Reese, S., Jr. ; 15210 Redwood Run Court, Houston, TX 77062 (US). WERNICKE, Joachim, F. ; 2605 Ryder Court, League City, TX 77573 (US).</p> <p>(74) Agents: GREENE, Donald, R. et al.; Leitner, Greene & Christensen, 1735 Jefferson Davis Highway, Suite 203, Arlington, VA 22202 (US).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: TREATMENT OF SLEEP DISORDERS BY NERVE STIMULATION



(57) Abstract

Method and apparatus (10) for treating and controlling sleep disorders by detecting (37) the presence of the sleep disorder under treatment, and, in response, selectively applying a predetermined generated (12-17, 19, 23) electrical signal to the patient's vagus nerve for stimulation thereof to alleviate the sleep disorder under treatment. The method and apparatus includes several techniques for detecting (37) the presence of the sleep disorder under treatment, such as sensing the patient's EEG activity in the case of insomniac and hypersomnia patients, or detecting a sudden nodding of the head in the case of narcoleptic patients, or sensing the cessation of respiration in the case of sleep apnea patients.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

TREATMENT OF SLEEP DISORDERS BY NERVE STIMULATION

Background of the Invention

The present invention relates generally to methods and apparatus for treating or controlling medical, psychiatric or neurological disorders by application of modulating electrical signals to a selected nerve or nerve bundle of the patient, and more particularly to techniques for treating patients with sleep disorders by application of such signals to a cranial nerve, using an implantable neurostimulating device. Specifically, the invention is directed toward treating various sleep disorders, such as insomnia, hypersomnia, apnea, and narcolepsy, by selective modulation of vagus nerve electrical activity.

Sleep is not a uniform state, but rather involves several stages characterized by changes in the individual's EEG. Stage 1 sleep is drowsiness, in which the EEG displays a lower voltage, more mixed frequencies and deterioration of alpha rhythm relative to the EEG when the individual is awake, even when in a relaxed state. In stage 2, background activity similar to that of stage 1 is experienced, with bursts of slightly higher frequency "sleep spindles" and sporadic higher amplitude slow wave complexes. The third and fourth stages of sleep display increasing high amplitude slow wave activity. A separate sleep stage is one in which the individual undergoes rapid eye movements (REM) with lower voltage, higher frequency EEG and other characteristics similar to those which occur when the individual is awake, whereas the other four sleep stages are categorized as non-REM (NREM) sleep.

Normally, the extent to which NREM stages and REM sleep are experienced, as well as the sleep requirements of the individual, are largely age dependent. Adults typically pass in sequence through the four stages of NREM sleep, and may enter several spaced periods of REM sleep during the night. Adults usually require only six or seven hours of sleep, while infants require sleep during both day and night

(normally 50% of the sleep time being spent in REM sleep), and the aged require less sleep than the adult and may experience no REM sleep.

The principal sleep disorders are central sleep apnea, insomnia and hypersomnia, and the syndromes thereof. Other sleep disorders include sleep walking and enuresis (nocturnal incontinence, or bed-wetting). The latter two disorders are primarily confined to children. Insomnia is a chronic inability to sleep or to remain asleep throughout the night, and is usually suffered as a result of various physical and/or physiologic factors, such as pain, discomfort, anxiety, depression, tension, and obstructive sleep apneas. Sleep apneas are characterized by brief episodes of respiratory arrest, which may occur many times during sleep and may be associated with obstruction of the upper airways, cessation of diaphragmatic movements and snoring. Hypersomnia is a condition in which the individual undergoes sleep of excessive depth or abnormal duration, usually caused by physiologic rather than physical factors and characterized by a state of confusion on awakening. Daytime hypersomnia, which may complicate sleep apnea, is commonly represented by the narcoleptic syndrome, characterized by sudden sleep attacks, cataplexy, sleep paralysis, and visual or auditory hallucinations at the onset of sleep.

Conventional treatment of insomnia typically involves hypnotics (drugs employed as sedatives), while treatment of narcolepsy and other syndromes of hypersomnia often utilizes stimulant drugs such as dextro- and laevo-amphetamine and methylphenidate. Unfortunately, however, treatment with drugs has not proved very effective and often results in undesirable side-effects.

It is a principal object of the present invention to apply techniques of selective modulation of the electrical activity of a cranial nerve, and particularly the vagus nerve, to treat and control at least the principal sleep disorders, including sleep apnea, insomnia, hypersomnia, narcolepsy, and syndromes thereof.

In addressing a therapy involving nerve stimulation to treat sleep disorders, notice should be taken of existing knowledge that most nerves in the human body are composed of thousands of fibers, having different sizes designated by groups A, B and C, carrying signals to and from the brain and other parts of the body. The vagus nerve, for example, may have approximately 100,000 fibers (axons) of the three different types, each of which carries such signals. Each axon of that nerve only conducts in one direction, in normal circumstances. The A and B fibers are myelinated, that is, they have a myelin sheath in the form of a substance largely composed of fat. On the other hand, the C fibers are unmyelinated.

Myelinated fibers are typically larger, have faster electrical conduction and much lower electrical stimulation thresholds than the unmyelinated fibers. Along with the relatively small amounts of electrical energy needed to stimulate the myelinated fibers, it is noteworthy that such fibers exhibit a particular strength-duration curve in response to a specific width and amplitude of stimulation pulse.

The A and B fibers are stimulated with relatively narrow pulse widths, from 50 to 200 microseconds (μ), for example. A fibers exhibit slightly faster electrical conductivities than the B fibers, and slightly lower electrical stimulation thresholds. The C fibers are relatively much smaller, conduct electrical signals very slowly, and have high stimulation thresholds typically requiring wider pulse widths (e.g., 300-1000 μ) and higher amplitudes for activation. Although the A and B fibers may be selectively stimulated without also stimulating the C fibers, the magnitude and width of the pulse required for stimulating the C fibers would also activate A and B fibers.

Although electrical stimulation of the nerve fiber typically activates neural signals in both directions (bidirectionally), selective unidirectional stimulation is achievable through the use of special nerve electrodes and

stimulating waveforms. As noted above, each axon of the vagus nerve normally conducts in only one direction.

5 In a paper on the effects of vagal stimulation on experimentally induced seizures in rats (Epilepsia (1990) 31 (Supp 2): S7-S19), Woodbury has noted that the vagus nerve is composed of somatic and visceral afferents (i.e., inward conducting nerve fibers which convey impulses toward a nerve center such as the brain or spinal cord) and efferents (i.e., outward conducting nerve fibers which convey impulses to an effector to stimulate it and produce activity). The vast majority of vagal nerve fibers are C fibers, and a majority are visceral afferents having cell bodies lying in masses or ganglia in the neck. The central projections terminate, by and large, in the nucleus of the solitary tract which sends 10 fibers to various regions of the brain (e.g, the hypothalamus, thalamus, and amygdala); others continue to the medial reticular formation of the medulla, the cerebellum, the nucleus cuneatus and other regions.

Woodbury further notes that stimulation of vagal 20 nerve afferent fibers in animals evokes detectable changes of the EEG in all of these regions, and that the nature and extent of these EEG changes depends on the stimulation parameters. Chase, in Exp Neurol (1966) 16:36-49, had also observed that vagal activation can affect the EEG activity 25 of certain parts of the brain. The applicants herein postulate that synchronization of the EEG may be produced when high frequency (> 70 Hz) weak stimuli activate only the myelinated (A and B) nerve fibers, and that desynchronization of the EEG occurs when intensity of the stimulus is increased to a level that activates the unmyelinated (C) nerve fibers. 30 Woodbury also observes that vagal stimulation can produce widespread inhibitory effects on seizures and certain involuntary movements.

Extra-physiologic electrical stimulation of the 35 vagus nerve has previously been proposed for treatment of epilepsy and various forms of involuntary movement disorders. Specifically, in U.S. Patent 4,702,254 issued October 27,

1987 to J. Zabara (referred to herein as "the '254 patent"), a method and implantable device are disclosed for alleviating or preventing epileptic seizures, characterized by abnormal neural discharge patterns of the brain. The '254 patent describes an implantable neurocybernetic prosthesis (NCP) which utilizes neurocybernetic spectral discrimination by tuning the external current of the NCP generator to the electrochemical properties of a specific group of inhibitory nerves that affect the reticular system of the brain. These nerves are embedded within a bundle of other nerves, and are selectively activated directly or indirectly by the tuning of the NCP to augment states of brain neural discharge to control convulsions or seizures. According to the patent, the spectral discrimination analysis dictates that certain electrical parameters of the NCP pulse generator be selected based on the electrochemical properties of the nerves desired to be activated. The patent further indicates that the optimum sites for application of the NCP generator output to produce the desired effects are the cranial nerves in general, and the vagus nerve in particular.

The NCP disclosed in the '254 patent may be activated either manually or automatically, to provide treatment for the duration of the seizure. Manual activation is performed when the patient experiences the aura at onset of the seizure. Alternatively, automatic activation may be triggered upon detection of instantaneous changes in certain state parameters immediately preceding or at onset of a seizure. Additionally, a prophylactic or preventive mode may be employed in which the NCP is activated periodically to reduce the occurrence and/or the intensity of the seizures. The NCP stimulator of the '254 patent is implanted in the patient's chest and is connected to electrodes installed at the selected point of signal application at the nerve site with the more negative electrode situated closer to the brain and the positive electrode further from the brain, along the vagus nerve.

There is substantial evidence to indicate that sleep is modulated by brain stem centers. Because these centers receive input from the vagus nerve, their activity can be affected by vagal stimulation. The following are some scientific papers of interest on this subject. In Exp. Brain Res. Suppl. (1984) 8:3-18, Sakai describes synchronized sleep (NREM) and desynchronized sleep (REM) and the brain centers which control them in the cat. Puizillout et al. showed, in Brain Res. (1976) 11:181-184, that vagal stimulation may increase the number or duration of REM episodes, the total amount of REM being found constant; and, in Electroencephalog. Clin. Neurophysiol. (1977) 42:552-563, that sleep cycles may be induced by stimulation of the vagus nerve. Another Puizillout et al. group reviewed, in Exp. Brain Res. Suppl. (1984) 8:20-38, literature on the evidence for involvement of the nucleus of the solitary tract and vagal afferents in modulation of sleep cycles. In Brain Res. Bull. (1985) 15:437-441, Juhasz et al. showed that vagal stimulation directly affects reticular and ventro-posterior-medial nuclei of the cat thalamus; neural activity recorded depended on stimulus parameters, sleep state and site of recording.

Summary of the Invention

The present invention is directed to methods and devices for treating and controlling sleep disorders by selective stimulation of the vagus nerve (the tenth cranial nerve) in a predetermined manner to modulate its electrical activity, and thereby synchronize or desynchronize the patient's EEG and/or modify the patient's sleep patterns according to the specific nature of the sleep disorder under treatment. In general, the normal EEG of an awake subject exhibits low voltage and relatively fast activity. Normally also, the EEG activity slows down during sleep, and displays higher voltage. NREM sleep stage patterns and REM sleep patterns have been discussed briefly in the above background section of this document.

In the preferred methods of the invention, disorders associated with abnormally little sleep (insomnia) are treated by modulating the patient's vagal activity with electrical signal parameters which produce a high voltage synchronous EEG typically seen in the intermediate stages of sleep; whereas disorders associated with abnormally excessive sleep (in terms of suddenness, depth or duration) are treated by modulating the patient's vagal activity with electrical signal parameters or stimuli which desynchronize the patient's EEG activity. Both of these categories may employ a sensing (automatic) mode and/or a patient (manual) activation mode for delivery of the therapy.

The apparatus of the invention includes a neurostimulator (preferably but not necessarily implantable) to selectively apply the desired therapy to treat the sleep disorder of interest by modulating the electrical activity of the patient's vagus nerve in a predetermined manner. The neurostimulator is programmed by the attending physician to provide the desired therapeutic modality for that purpose.

Selection among various strategies for vagal modulation to treat the sleep disorder depends on a number of factors. These include (i) a consideration of which of the nerve fibers are to be subjected to stimulation; (ii) the modality for achieving synchronization or desynchronization of the EEG; (iii) whether some type of physiologic signal is generated which can be detected and employed to trigger the modulation; and/or (iv) whether a "carryover" or refractory period occurs after modulation in which the benefit of the modulation is maintained. Although these are not all of the factors to be considered for selecting a stimulation strategy for treatment of the disorder, nor necessarily listed in order of importance, they are indicative of considerations which may apply in a specific case.

In the treatment according to the invention, different signal parameters and threshold curves are used to activate the various fibers of the patient's vagus nerve for selective modulation of the electrical activity thereof. By

appropriately setting pulse width and amplitude of the electrical signal to be delivered by the neurostimulator to the patient's vagus nerve, the nerve fibers can be selectively stimulated, such as A and not B and C; or A and B, but not C; or A, B and C. Various related factors, however, must be considered in the selection process. For example, because the C fibers conduct signals very slowly, they are not highly responsive to techniques of fast stimulation. Therefore, if it were desired to increase desynchronous activity of the EEG by stimulation of the C fibers at 50 Hz, for example, for treatment of narcolepsy in a particular patient, it would be prudent to use a short pulse train for the stimulus. This is because the fibers would become refractory to the stimulation within a relatively short time interval and thus incapable of tracking the pattern of a longer train. After a suitable recovery period, another short pulse train may be applied to achieve further treatment. The precise pattern to be used, e.g., the length of the time intervals on and off, will depend upon and be adjusted to the individual patient and the particular sleep disorder being treated.

Furthermore, proper designation of amplitude and frequency range of the applied signals allows tuning of the fibers for EEG synchronization or desynchronization, for control of the disorder. Desynchronization of the EEG has been found to be achieved by stimulation of the vagus nerve at frequencies in the range from 20 to 75 Hz at levels above 0.1 volt, but requires signals greater than 3 volts at frequencies above 75 Hz. If the frequency is above 75 Hz and the signal is below 3 volts, EEG synchronization is achieved. The actual voltage required depends on the type and geometry of the electrode and the impedance of the electrode-tissue interface.

According to the invention, the basic stimulation strategy is to modulate the electrical activity of the vagus nerve to synchronize or desynchronize the patient's EEG, and, in appropriate cases, to produce the desired patterns of REM and NREM sleep, depending on the particular sleep disorder

and the individual patient. In part, this involves modulating the activity of a number of brain structures, including the limbic system, the hippocampus, and the reticular formation, the latter being of particular importance in the control of sleep. As described by Rutecki in Epilepsia (1990) 31 (Supp. 2): S1-S6, the vagus nerve projects directly or indirectly to these brain structures. The strategy may be implemented by use of a detection system specific to the sleep disorder of interest, including, if necessary, sense signal analysis circuitry, to trigger automatic stimulation of the vagus nerve. Alternatively or additionally, the neurostimulator may be adapted for manual activation by the patient upon recognizing onset or continuation of the disorder (such as inability to sleep, or an overwhelming desire to sleep). For example, for automatic delivery of the stimulus therapy to the narcoleptic patient, surface electrodes may be implanted in the head to measure EEG activity, and to activate the neurostimulator to deliver stimuli for desynchronizing the synchronous high voltage slow wave EEG activity and increasing the background desynchronous activity upon detection of sudden synchronous EEG activity. A more simple, but effective detection strategy for narcolepsy attacks is to implant a miniaturized motion detector to sense a sudden drop of the patient's head. For sleep apnea, the detection may be of the respiratory muscle (chest) movement or of air flow through the nostril(s), to trigger stimulation at onset of an apneic episode.

A stimulation strategy which does not require specific detection involves the use of circadian or other rhythmic programming to automatically activate vagal stimulation in a manner to induce sleep during the normal nighttime cycle for the insomniac patient, or to arouse and stimulate alertness during the normal daytime cycle for the hypersomniac patient. In general, however, a detection strategy appropriate to the disorder of interest is selected to initiate the proper stimulation strategy.

Broadly, then, the present invention is directed to apparatus and methods which employ a neurostimulator device, preferably implantable, for therapy or treatment of sleep disorders through nerve stimulation. The modulating signals applied to the vagus nerve may stimulate or inhibit neural signals to produce excitatory or inhibitory neurotransmitter release, but for purposes of this disclosure both situations are included within the term "stimulating". It should be emphasized that although the preferred nerve site for application of the modulating signals is the vagus nerve, effective treatment may be achieved through application of the stimulus to one or more other nerves, particularly among the cranial nerves, and such treatment is deemed to be within the ambit of the present invention.

Accordingly, it is another object of the present invention to apply the techniques of selective modulation of vagus nerve electrical activity, using a neurostimulator device which may be implantable, or disposed external to the body with only a small portion of the circuitry implanted or with only the nerve electrode(s) and associated lead(s) implanted percutaneously in the body, to the treatment or control of sleep disorders.

A more specific object of the invention is to provide methods and apparatus responsive to detected symptoms characteristic of or associated with certain sleep disorders for applying preprogrammed electrical stimuli to a cranial nerve and particularly the vagus nerve of the patient to modulate the electrical activity of afferent fibers of the nerve as part of a therapy designed to treat or control the specific disorder, such as by selectively synchronizing or desynchronizing the patient's EEG in the case of the insomniac or hypersomniac patient, respectively.

Another object of the invention is to provide methods of treating and controlling a sleep disorder by sensing a symptom of the disorder and automatically or manually responding thereto by modulating electrical activity of the appropriate brain or brain stem centers through the

application of preselected stimuli to the patient's vagus nerve.

Brief Description of the Drawings

5 The above and still further objects, aspects, features and attendant advantages of the present invention will be better understood from a consideration of the ensuing detailed description of a presently preferred embodiment and method thereof, taken in conjunction with the accompanying drawings, in which:

10 FIG. 1 is a simplified block diagram of an implantable neurostimulator electronics package (stimulus generator) for use (with appropriate parameter settings and ranges) in treating sleep disorders according to the present invention;

15 FIG. 2 is a simplified fragmentary illustration of a preferred embodiment of the stimulus generator and lead/electrode system of the neurostimulator implanted in the patient's body, and of sensor systems suitable for detecting certain sleep disorders;

20 FIG. 3 is a detailed fragmentary illustration of the nerve electrode as implanted on the vagal nerve in the neck of the patient for modulating vagal activity;

25 FIG. 4 is an illustrative idealized electrical output signal waveform of the stimulus generator useful for clarifying relevant parameters of the signal developed by the stimulus generator for application to the nerve;

FIG. 5 is a simplified block diagram of an EEG spectral analysis circuit which may be used in the stimulus generator in conjunction with an EEG detection system useful for treating insomnia and hypersomnia; and

30 FIG. 6 is another simplified fragmentary illustration, similar to that of FIG. 2, but here, of exemplary sensor systems suitable for detecting sleep apnea and narcolepsy attacks and which may be worn externally by or implanted in the patient.

Description of the Presently Preferred Embodiments and Methods

Referring now to the drawings, a block diagram of the basic components of the stimulus generator of a neurostimulator and their interrelationship is illustrated in FIG. 1, and further details of location of an implantable version of the device and the associated lead/electrode system are shown in FIGS. 2 and 3. A generally suitable form of neurostimulator for use in the apparatus of the present invention is disclosed in copending U.S. patent application Ser. No. 07/434,985, filed November 10, 1989 in the names of Anthony J. Barrichio, et al. (referred to herein as "the '85 application"), assigned to the same assignee as the instant application. The specification of the '85 application is incorporated herein in its entirety by reference, but certain portions of it are summarized in this application for the sake of convenience to the reader.

The neurostimulator utilizes a conventional microprocessor and other standard electrical and electronic components, and in the case of an implanted device, communicates with a programmer and/or monitor located external to the patient's body by asynchronous serial communication for controlling or indicating states of the device. Passwords, handshakes and parity checks are employed for data integrity. The neurostimulator also includes means for conserving energy, which is important in any battery operated device and especially so where the device is implanted for medical treatment of a disorder, and means for providing various safety functions such as preventing accidental reset of the device.

The stimulus generator 10 (FIG. 1) is preferably adapted to be implantable in the patient's body, in a pocket formed by the surgeon just below the skin in the chest as shown in FIG. 2, although a primarily external neurostimulator may alternatively be employed. The neurostimulator also includes implantable stimulating electrodes (described below) together with a lead system 22 for applying the output signal

of the stimulus generator to the patient's vagus nerve. Components external to the patient's body include a programming wand for telemetry of parameter changes to the stimulus generator and monitoring signals from the generator, and a
5 computer and associated software for adjustment of parameters and control of communication between the generator, the programming wand and the computer. These external components of the system are not shown in the drawings.

In conjunction with its microprocessor-based logic
10 and control circuitry, the stimulus generator 10 or other implanted or external circuitry includes detection circuitry for sensing an event indicative of onset or ongoing presence of the sleep disorder to trigger automatic delivery of the stimulating signal. For example, EEG surface or depth elec-
15 trodes may be implanted to sense EEG characteristics associated with the particular disorder, eye movement sensors may be implanted to detect REM or NREM sleep, a respiration detector may be implanted in or worn externally by the sleep apnea patient to sense cessation of breathing, or an acceler-
20 ometer may be implanted in the narcoleptic patient to respond to a sudden attack of deep sleep, in each case to trigger the appropriate vagal stimulation therapy programmed into the neurostimulator for the individual patient. Further details of the detection systems will be discussed presently herein.
25 Use of certain sensors, such as depth EEG electrodes, may involve more delicate electrode/lead implantation procedures and the need for associated analyzing circuitry not required with others, but the use of such sensors can be the most suitable and accurate technique presently achievable for
30 detecting the serious sleep disorder of interest and initiating appropriate therapy. The stimulus generator is designed, implemented and programmed to deliver a selectively patterned stimulating signal to modulate the electrical activity of the vagus nerve in a manner designed to treat and control the
35 disorder.

As shown in FIG. 1, stimulus generator 10 includes a battery (or set of batteries) 12, which may be of any

reliable long-lasting type conventionally employed for powering implantable medical electronic devices (such as batteries employed in implantable cardiac pacemakers or defibrillators). In the preferred embodiment of the stimulus generator, the battery is a single lithium thionyl chloride cell. The terminals of the cell 12 are connected to the input side of a voltage regulator 13. The regulator smoothes the battery output to produce a clean, steady output voltage, and provides enhancement thereof such as voltage multiplication or division if necessary for a specific application.

Regulator 13 supplies power to logic and control section 15, which includes a microprocessor and controls the programmable functions of the device. Among these programmable functions are output current or voltage, output signal frequency, output signal pulse width, output signal on-time, output signal off-time, daily treatment time for continuous or periodic modulation of vagal activity, and output signal-start delay time. Such programmability allows the output signal to be selectively crafted for application to the stimulating electrode set (FIGS. 2 and 3) to obtain the desired modulation of vagal activity for treatment and control of the specific sleep disorder. Timing signals for the logic and control functions of the generator are provided by a crystal oscillator 16. A magnetically-actuated reed switch 14 is incorporated in the electronics package to provide the generator with the capability for patient activation thereof (by use of an external magnet, not shown, placed immediately adjacent to the package or its implant site).

Built-in antenna 17 enables communication between the implanted stimulus generator and the external electronics (including both programming and monitoring devices) to permit the device to receive programming signals for parameter changes, and to transmit telemetry information, from and to the programming wand. Once the system is programmed, it operates continuously at the programmed settings until they

are reprogrammed (by the attending physician) by means of the external computer and the programming wand.

Logic and control section 15 of the stimulus generator 10 controls an output circuit or section 19 which generates the programmed signal levels appropriate to the disorder being treated. The output section and its programmed output signal are coupled (directly, capacitively, or inductively) to an electrical connector 20 on the housing 21 of the generator and to lead assembly 22 connected to the stimulating electrodes (FIGS. 2 and 3). A sense signal analysis circuit 23 is provided within the generator housing 21, with connections to the microprocessor in logic and control section 15 and to the sensing electrodes. An exemplary sense signal analysis circuit for use with implanted EEG sensing electrodes to cause the microprocessor to trigger delivery of therapy by the output circuit of the generator on detection of a selected event, is shown in FIG. 5 and will be described presently. The parameters of the stimulating signal of the implanted device may be calibrated by telemetry (via the programming wand) according to the needs of the particular patient and the results then programmed into the microprocessor for delivery of the appropriate treatment upon activation of the stimulus generator.

Housing 21 in which stimulus generator 10 is encased is hermetically sealed and composed of a material such as titanium which is biologically compatible with the fluids and tissue of the patient's body. Further details of suitable structure and operation of the neurostimulator, beyond those by which the device is adapted to treat the disorder as described herein, are available in the '985 application, to which the reader is referred.

FIG. 2 illustrates the preferred location of implanted generator 10, in case 21 with connector 20, in the patient's chest in a cavity formed by the implanting surgeon just below the skin, much as a pacemaker pulse generator would be implanted. A stimulating nerve electrode set 25 (FIG. 3) is conductively connected to the distal end of

insulated electrically conductive lead assembly 22 which is attached at its proximal end to connector 20. Electrode set 25 is a bipolar stimulating electrode, preferably of the type described in U.S. Patent 4,573,481 issued March 4, 1986 to Bullara. The electrode assembly is surgically implanted on the vagus nerve 27 in the patient's neck. The two electrodes 25-1 and 25-2 are wrapped about the vagus nerve, and the assembly is secured to the nerve by a spiral anchoring tether 28 preferably as disclosed in U.S. Patent 4,979,511 issued December 25, 1990 to Reese S. Terry, Jr. and assigned to the same assignee as the instant application. Lead(s) 22 is secured, while retaining the ability to flex with movement of the chest and neck, by a suture connection 30 to nearby tissue.

The open helical design of electrode assembly 25 (described in detail in the above-cited Bullara patent), which is self-sizing and flexible, minimizes mechanical trauma to the nerve and allows body fluid interchange with the nerve. The electrode assembly conforms to the shape of the nerve, providing a low stimulation threshold by allowing a larger stimulation contact area. Structurally, the electrode assembly comprises two ribbons of platinum constituting the electrodes which are individually bonded to the inside surface of each of the first two spiral loops 25-1 and 25-2 of a three-loop helical assembly, and the two lead wires are respectively welded to the conductive ribbon electrodes. The remainder of each loop is composed of silicone rubber, and the third loop acts as the tether 28 for the electrode assembly. The inner diameter of the helical bipolar electrode assembly may typically be approximately two millimeters (mm), and an individual spiral is about seven mm long (measured along the axis of the nerve).

For purposes of detecting the EEG characteristics associated with insomnia or hypersomnia sleep disorder, depth EEG sense electrodes 36 may be implanted in spaced apart relation through the skull, and connected to leads 37 implanted via a catheter or other suitable means (not shown)

and extending along the scalp and temple and then along the jawline through the neck and chest tissue to the sense signal analysis circuit 23 of stimulus generator 10. Alternatively, or additionally, if prescribed by the attending physician, eye movement sensing electrodes 33 may be implanted at or near the outer periphery of each eye socket in a suitable location to sense muscle movement, or actual eye movement by placement about the nerves which control such movement, as shown in FIG. 2. The sense electrodes 33 are utilized to detect REM and NREM sleep, and are electrically connected to leads 34 implanted and extending toward the ears and then generally along the same path and in the same manner as described above for the EEG sense electrode leads. In this case, the signal analysis circuit would be simplified, consisting for example of a logic circuit which generates an activation command to the microprocessor upon detecting a predetermined count within a set period of time, indicative of REM sleep.

For sleep apnea patients, the cessation of respiration is detected, in a preferred embodiment, by an externally-positioned breathing sensor placed in the patient's nostril as shown at 50 in FIG. 6. A suitable breathing sensor merely detects the presence or absence of nasal air flow and is worn in or near one nostril, only at night or anytime that the patient retires to sleep, such as at nap times for infant or elderly patients. Processing of the nasal air flow signal is performed by a suitable external circuit 53 which is adapted to generate an activation command to the microprocessor of logic and control circuit 15. A suitable processing circuit is an external RF signal generator positioned in the vicinity of the implanted stimulus generator 10 and triggered by a sustained absence of nasal air flow for a predetermined interval of time. The selected time interval should be sufficiently long to reasonably assure that the patient has stopped breathing momentarily, and yet sufficiently short to allow the detection to be made

and the vagal stimulation to be commenced before the patient's sleep is interrupted.

Although external devices are less attractive than implants to most patients, in this instance the cosmetic considerations are less significant because the external devices are worn or used by the sleep apnea patient only at times when the intention or expectation is to sleep. However, a totally implanted respiration detection system may be employed, if desired, for example using a device which senses movement of the patient's diaphragm associated with normal breathing. Preferably, the diaphragm movement is sensed by an impedance detector, or alternatively, by plural electrodes for detecting physical movement of the muscle, implanted in the chest of the patient as shown generally at 60 in FIG. 6. The detector generates a signal indicative of absence of diaphragm movement for a time interval set according to the above-mentioned criteria, which is conveyed by implanted lead 62 to trigger application of vagal stimulation by generator 10 under the command of the microprocessor.

For the narcoleptic patient, a miniaturized accelerometer in the form of a movement detecting electronic or electromechanical switch, for example, may be implanted beneath the skin as generally shown at 65 in FIG. 6. The accelerometer position is selected to respond to sudden nodding or dropping of the patient's head, which results from the brief attack of deep sleep characteristic of narcolepsy, to generate a signal on implanted lead 67 to trigger stimulation of the vagus nerve.

The stimulus generator may be programmed with an IBM-compatible personal computer (not shown) using programming software of the type copyrighted by the assignee of the instant application with the Register of Copyrights, Library of Congress, or other suitable software based on the description herein, and a programming wand (not shown). The wand and software permit noninvasive communication with the generator after the latter is implanted. The wand is preferably powered by internal batteries, and provided with

a "power on" light to indicate sufficient power for communication. Another indicator light is preferably provided to show that data transmission is occurring between the wand and the generator.

5 The operation of stimulus generator 10 to control and treat sleep disorders will be described with reference to FIG. 4, which illustrates the general nature, in idealized representation, of the output signal waveform delivered by
10 output section 19 of the neurostimulator to electrode assembly 25. This illustration is presented principally for the sake of clarifying terminology, including the parameters of output signal on-time, output signal off-time, output signal frequency, output signal pulse width, and output signal current or voltage.

15 In the treatment of sleep disorders according to the invention, the stimulation strategy is to program the neurostimulator to synchronize the patient's EEG activity in the case of insomniac patients, and to desynchronize the EEG activ-ity in the case of hypersomniac, narcoleptic or sleep
20 apnea patients. For synchronization, the parameters of the stimulus signal may be programmed, for example, at a frequency of 90 Hz, an output current of 1.0 mA, and a pulse width of 0.10 ms for the pulse waveform. For desynchronization, the corresponding parameters of an exemplary pulse waveform
25 would be 20 Hz, 1.5 mA, and 0.5 ms. A patient suffering from insomnia may simply activate the neurostimulator when he or she is unable to sleep. This may be accomplished in a number of different ways, one example being to place an external magnet directly over the site of the implanted stimulus
30 generator to actuate the reed switch 14 (FIG. 1).

 A suitable range of stimulation parameters for synchronization or desynchronization of the patient's EEG activity, as appropriate, and the typical value of each parameter of the stimulating output signal for treatment of
35 the disorder are as follows:

	<u>Range</u>	<u>Desynch, Typical</u>	<u>Synch, Typical</u>
Pulse Width	0.05 - 1.5 ms	0.5 ms	0.1 ms
Output Current	0.1 - 5.0 mA	1.5 mA	1.0 mA
5 Frequency	5 - 150 Hz	20 Hz	90 Hz
ON Time	5 - 5000 sec	300 sec	30 sec
OFF Time	5 - 5000 sec	20 sec	30 sec
Frequency sweep	10 - 100 Hz	Optional	
Random frequency	10 - 100 Hz	Optional	

10 As noted earlier herein, a technique for initiating stimulation without a specific detection system requires that the neurostimulator be programmed according to the circadian rhythm of the particular patient and the disorder being treated, to either desynchronize or synchronize the patient's

15 EEG activity as appropriate.

A signal analysis circuit 23 for stimulus generator 10 (FIG. 1), suitable for processing the EEG waveform developed by surface or depth EEG electrodes, is shown in greater detail in FIG. 5. In this exemplary embodiment, the

20 sensing electrodes are EEG electrodes such as 36 and associated leads 37 of FIG. 2, and the analysis circuit 23 is implemented for EEG detection and analysis. To that end, circuit 23 includes a plurality of parallel active sense signal bandpass filters 40 staged to provide selective

25 filtering in the ranges from 0-2 Hz, 2-4 Hz and 15-20 Hz, for example; a logic circuit 42 to select the output of one filter from among the plurality of filters 40; and an analog/digital (A/D) converter 45. The outputs of the filters are individually sampled by the logic circuit 42, and

the sampling rate, averaging time interval, and weighting assigned to each sense signal band are controlled by the microprocessor in the logic and control section 15 of the stimulus generator 10 (FIG. 1), to detect the EEG pattern.

5 When the selected event is detected, the processed digital signal is supplied to the microprocessor to trigger application of the stimulating signal to the patient's vagus nerve.

As specified above, other types of signal processing circuits may be used depending on the specific type of detection required, or, in some instances, the output of the sensing device itself may be used directly without further processing.

10

Various features may be incorporated into the neurostimulator for purposes of the safety and comfort of the patient. For example, comfort would be enhanced by programming the output stimulus to ramp up during the first two seconds of stimulation, rather than to be delivered abruptly. Also, the implanted generator may be provided with a clamping circuit to limit the maximum voltage, to 14 volts for example, which is delivered to the vagus nerve. Such a maximum limit is designed to prevent injury to the patient's vagus nerve.

15

20

The programmable functions and capabilities of the neurostimulator are designed and implemented to permit noninvasive communication with the stimulus generator after it is implanted, which is useful for both activation and monitoring functions. Beyond the essential functions of the device, the programming software may readily be structured

25

to provide straightforward menu-driven operation, HELP functions, prompts, and messages to facilitate simple and rapid programming while keeping the user fully informed of everything occurring at each step of a sequence. Programming capabilities should include capability to modify the adjustable parameters of the stimulus generator and its output signal, to test device diagnostics, and to store and retrieve telemetered data. It is desirable that when the implanted unit is interrogated, the present state of the adjustable parameters is displayed on the monitor of external PC so that the programmer may then conveniently change any or all of those parameters at the same time; and, if a particular parameter is selected for change, all permissible values for that parameter are displayed so that the programmer may select an appropriate desired value for entry into the neurostimulator.

Diagnostics testing should be implemented to verify proper operation of the device, and to indicate the existence of problems such as with communication, the battery, or the lead/electrode impedance. A low battery reading, for example, would be indicative of imminent end of life of the battery and need for implantation of a new device. The nerve electrodes are capable of indefinite use absent indication of a problem with them observed on the diagnostics testing.

Although a preferred embodiment and methods of treating and controlling sleep disorders according to the invention have been described herein, it will be apparent to those skilled in the field from a consideration of the

foregoing description that variations and modifications of such embodiments, methods and techniques may be made without departing from the true spirit and scope of the invention. For example, although a totally implantable neurostimulator device is preferred (with the possible exception of the detection system), the electronic energization package may, if desired, be primarily external to the body. Stimulation can be achieved with an RF power device implemented to provide the necessary energy level. The implanted components may be limited to the lead/electrode assembly, a coil and a DC rectifier. Pulses programmed with the desired parameters would be transmitted through the skin with an RF carrier, and the signal thereafter rectified to regenerate a pulsed signal for application as the stimulus to the vagus nerve to modulate vagal activity. This would virtually eliminate the need for battery changes. The disadvantages of such an implementation are that the external transmitter must be carried by the patient, greater power is required for activation, and the output current to the nerve is less stable.

An external stimulus generator may be employed with leads extending percutaneously to the implanted nerve electrode set. The major problem encountered with this technique is the potential for infection, but it is useful to allow short term testing of the patient to determine whether the sleep disorder suffered by the patient under observation is amenable to successful treatment. If it is, a more permanent implant may be provided.

Accordingly, it is intended that the invention shall be limited only to the extent required by the appended claims and the rules and principles of applicable law.

What is claimed is:

1. A method of treating patients with sleep disorders, which includes

detecting an event indicative of the sleep disorder to be treated, and

upon detection of said event, selectively applying a predetermined electrical signal to the patient's vagus nerve for stimulation thereof to alleviate the sleep disorder under treatment.

2. The method of claim 1, wherein

the predetermined electrical signal is programmable to modulate the electrical activity of the vagus nerve to control the EEG activity of the patient.

3. The method of claim 2, wherein

the predetermined electrical signal is a pulse waveform with signal parameters programmable to synchronize or desynchronize the patient's EEG activity according to the nature of the sleep disorder under treatment.

4. The method of claim 3, wherein

the detected event is one of (i) a desynchronous EEG pattern indicative of inability of the patient to sleep during nighttime hours, and (ii) a synchronous EEG pattern indicative of overwhelming desire of the patient to sleep during daytime hours; and

the pulse waveform is programmed to synchronize the patient's EEG activity upon detected event (i), and to desynchronize the patient's EEG activity upon detected event (ii).

5. The method of claim 1, wherein

the detected event includes one of (i) an EEG pattern of the patient reflecting presence of the sleep disorder under treatment, (ii) a sudden uncontrolled nodding of the patient's head, and (iii) a cessation of respiration by the patient.

6. The method of claim 5, wherein

the predetermined signal has electrical parameters programmed to stimulate the vagus nerve to cause desynchronization of the patient's EEG upon detected event (ii).

7. The method of claim 5, wherein

the predetermined signal has electrical parameters programmed to stimulate the vagus nerve to cause desynchronization of the patient's EEG upon detected event (iii).

8. The method of claim 1, wherein

the event is detectable by the patient, and the electrical signal is manually activatable.

9. The method of claim 3, wherein

the programmable signal parameters of the pulse

waveform include at least some of pulse width, output current or voltage, frequency, on time and off time.

10. The method of claim 3, wherein the disorder under treatment is insomnia, and

the pulse waveform signal parameters are programmed to synchronize the activity of the patient's EEG.

11. The method of claim 3, wherein the disorder under treatment is hypersomnia, and

the pulse waveform signal parameters are programmed to desynchronize the activity of the patient's EEG.

12. A method of treating patients with sleep disorder, which includes detecting the presence of the sleep disorder under treatment, and, in response thereto, selectively applying a programmed electrical signal to a selected cranial nerve of the patient to modulate the electrical activity of the selected cranial nerve in a predetermined manner to alleviate the sleep disorder under treatment.

13. The method of claim 12, wherein

said electrical signal is a pulse waveform with programmable signal parameters, and is applied to a nerve electrode implanted on the patient's vagus nerve.

14. The method of claim 13, wherein

the programmable parameter values of the pulse

waveform include pulse width, output current, frequency, on time and off time.

15. In a method of treating patients with sleep disorders, the step of applying an electrical signal with parameters programmed to alleviate the sleep disorder under treatment to the vagus nerve of the patient to modulate the electrical activity thereof at predetermined times and for predetermined time intervals during the patient's circadian cycle.

16. A device for treating sleep disorders in human patients, comprising:

stimulus means for generating a programmable electrical waveform,

implantable electrode means electrically connectable to said stimulus means for delivering said waveform to the vagus nerve of the patient, and

programming means for applying said waveform to said electrode means with selected parameter values of the waveform programmed to stimulate the vagus nerve to modulate the electrical activity thereof and thereby controllably vary the patient's EEG activity according to the nature of the sleep disorder under treatment.

17. The invention of claim 16, wherein

said programming means includes means for selecting the parameter values of the waveform to synchronize or

desynchronize the activity of the patient's EEG according to whether the sleep disorder under treatment is insomnia-related or hypersomnia-related, respectively.

18. The invention of claim 16, further including sensing means to detect an event indicative of the presence of the sleep disorder under treatment, for initiating the application of said waveform to said electrode means.

19. The invention of claim 16, wherein said programming means applies said waveform to said electrode means at predetermined times and for predetermined time intervals during the patient's circadian cycle.

20. The invention of claim 18, wherein said sensing means includes means for detecting the EEG activity of the patient.

21. The invention of claim 18, wherein said sensing means includes means for detecting a cessation of respiration of the patient.

22. The invention of claim 21, wherein said means for detecting cessation of respiration includes means responsive to the absence of movement of the patient's diaphragm.

23. The invention of claim 21, wherein
said means for detecting cessation of respiration
includes means responsive to the absence of nasal air flow
by the patient.

24. The invention of claim 18, wherein
said sensing means includes means for detecting a
sudden uncontrolled nodding of the patient's head.

1 / 3




FIG. 1




FIG. 4




FIG. 5

SUBSTITUTE SHEET

FIG. 3





FIG. 2




FIG. 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/03447

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61N 1/36

US CL :128/421

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/421; 128/419.00C, 419.00G, 419.00R, 422, 423, 00R, 723-724, 731, 782; 600/028

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US, A, 5,025,807 (ZABARA) 25 June 1991	
A	US, A, 4,715,367 (COSSLEY) 29 December 1987	
A	US, A, 4,830,008 (MEER) 16 May 1989	
A	US, A, 3,955,562 (FARRAR, JR.) 11 May 1976	
A	US, A, 3,363,242 (CURRY ET AL.) 09 January 1968	
A	US, A, 3,774,593 (HAKATA ET AL.) 27 November 1973	
A	US, A, 4,580,575 (BIRNBAUM ET AL.) 08 April 1986	
A	US, A, 2,831,181 (WARNER) 15 April 1958	
A	US, A, 3,584,618 (REINHARD) 05 June 1971	

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 25 AUGUST 1992	Date of mailing of the international search report 07 JUL
Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <i>W. E. Kamm</i> W. E. KAMM
Facsimile No. NOT APPLICABLE	Telephone No. (703) 308-0858

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.